CODX Research | Milton Maxwell

CODX

Co-Diagnostics, Inc.

0.2461

-0.0240-8.89%

Dec 16, 4:00:01 PM EST

Upcoming Earnings

Report date

-/-

Earnings Call Transcripts

This Quarter (Q1 '26)

No earnings call transcript available yet

Last Quarter (Q4 '25)

No earnings call transcript available

Key Stats

Market Cap

14.99M

P/E (TTM)

Basic EPS (TTM)

-0.98

Dividend Yield

Recent Filings

8-K

Nasdaq compliance regained

3/10/26Mar 10, 2026

Co-Diagnostics regained Nasdaq compliance with its $1.00 bid price rule on March 9, 2026, resuming trading March 11 under a one-year Discretionary Panel Monitor. Shares risk delisting without a grace period if below $1.00 for 30 straight business days. Cash stood at ~$11.9 million as of December 31, 2025 (preliminary). Compliance restored. Monitor looms.

8-K

Nasdaq delisting notice issued

1/13/26Jan 13, 2026

Co-Diagnostics faces Nasdaq delisting after failing the $1.00 minimum bid price rule, with trading suspended January 14, 2026, despite a 1-for-30 reverse split effective January 2. Shares have closed at or above $1.00 since then, prompting a hearing request and potential compliance by January 15. Delisting shifts trading to OTC Pink. No assurance of regaining Nasdaq status.

8-K

1-for-30 reverse split filed

12/30/25Dec 30, 2025

Co-Diagnostics approved and filed a 1-for-30 reverse stock split, effective January 1, 2026, slashing outstanding shares to approximately 2,095,031. Shares resume trading split-adjusted on Nasdaq under CODX on January 2. It's aimed at meeting the $1.00 minimum bid price for listing compliance. No assurance of lasting success.

8-K

Reverse split approved

12/5/25Dec 5, 2025

Co-Diagnostics shareholders approved a reverse stock split on December 5, 2025, authorizing a ratio from 1-for-2 to 1-for-30, with the board to decide within 12 months. The proposal passed decisively: 26.5 million for, 4.2 million against. Board holds the trigger.

10-Q

Q3 FY2025 results

11/13/25Nov 13, 2025

Co-Diagnostics posted Q3 revenue of $145K, down 77% y/y from $641K after grants dried up, yet narrowed its operating loss to $7.0M from $10.2M through cuts in legal costs and stock-based comp. Net loss improved to $5.9M or $(0.16) per share from $9.7M or $(0.32), confirmed against 37.9M diluted shares with anti-dilution from options/RSUs. Cash climbed to $11.4M on maturities and $4.8M equity raises, funding $22.9M operating burn; no debt. Registered direct closed September 2025 for $3.8M gross. Litigation clouds outcomes.

About

Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is based in Salt Lake City, Utah.

CEO

Mr. Dwight H. Egan

IPO

7/12/2017

Website

https://co-dx.com

Employees

132

Sector

Healthcare

Industry

Medical Devices